Company Innate Immunotherapeutics Ltd Australian S.E.
Equities
AU000000IIL6
Biotechnology & Medical Research
Business Summary
Sales per Business
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Focal Adhesion Kinase
100.0
%
| 0 | nan % | 0 | 100.0 % | - |
Sales per region
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Australia
100.0
%
| 0 | nan % | 0 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Founder | - | 30/05/00 | |
Tim Luscombe
DFI | Director of Finance/CFO | - | 24/09/23 |
Rhiannon Jones
COO | Chief Operating Officer | - | 31/01/21 |
Charlotte Mulder
PRN | Corporate Officer/Principal | - | - |
Mark Devlin
PRN | Corporate Officer/Principal | - | - |
Andrew Cooke
SEC | Corporate Secretary | 62 | 10/10/13 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Andrew Cooke
SEC | Corporate Secretary | 62 | 10/10/13 |
Robert Peach
BRD | Director/Board Member | 68 | 01/09/15 |
Warwick Tong
CHM | Chairman | - | 03/05/18 |
Founder | - | 30/05/00 | |
Jane Bell
BRD | Director/Board Member | - | 11/04/21 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 271,608,953 | 230,720,249 ( 84.95 %) | 0 | 84.95 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+9.42% | 114B | |
+11.84% | 104B | |
-14.15% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-4.16% | 17.89B | |
+7.99% | 14.28B | |
+36.24% | 12.55B |